Protection against cardiovascular diseases

Pomegranates: Ancient Roots to Modern Medicine

Volumn , Issue , 2006, Pages 63-89

  Fuhrman, Bianca ^a   Aviram, Michael ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85045914215     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (170)

1. Glass, C.K. and Witztum, J.L., Atherosclerosis: The road ahead, Cell, 104, 503, 2001.
2. Aviram, M., Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases, Free. Radic. Res., 33, S85, 2000.
3. Badimon, J.J. et al., A multifactorial disease, Circulation, 87, 13, 1993.
4. Ross, R., Atherosclerosis is an inflammatory disease, Am. Heart J., 138, S419, 1999.
5. Ross, R., Atherosclerosis - an inflammatory disease, N. Engl. J. Med., 340, 115, 1999.
6. Homma, Y., Predictors of atherosclerosis, J. Atheroscler. Thromb., 11, 265, 2004.
7. Lusis, A.J., Atherosclerosis, Nature, 407, 233, 2000.
8. Stocker, R. and Keaney, J.F., Jr., Role of oxidative modifications in atherosclerosis, Physiol. Rev., 84, 1381, 2004.
9. Alderman, M.H. et al., Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension, N. Engl. J. Med., 324, 1098, 1991.
10. Chobanian, A.V. and Dzau, V.J., Renin angiotensin system and atherosclerotic vascular disease, in Atherosclerosis and Coronary Artery Disease, Fuster, V., Ross, R., and Topol, E.J., eds. Vol. 1. Philadelphia: Lippincott-Raven, 1996, 237.
11. Keidar, S., Angiotensin, LDL peroxidation and atherosclerosis, Life Sci., 63, 1, 1998.
12. Daugherty, A., Manning, M.W., and Cassis, L.A., Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice, J. Clin. Invest., 105, 1605, 2000.
13. Weber, H., Taylor, D.S., and Molloy, C.J., Angiotensin II induces delayed mitogenesis cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin, J. Clin. Invest., 93, 788, 1994.
14. Larsson, P.T., Schwieler, J.H., and Wallen, N.H., Platelet activation during angiotensin II infusion to healthy volunteers, Blood Coagul. Fibrinolysis., 11, 61, 2000.
15. Keidar, S. et al., Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6, Arterioscler. Thromb. Vasc. Biol., 21, 1464, 2001.
16. Keidar, S., Kaplan, M., and Aviram, M., Angiotensin II modified LDL is taken up by macrophages via the scavenger receptor leading to cellular cholesterol accumulation, Arterioscler. Thromb. Vasc. Biol., 16, 122, 1996.
17. Keidar, S. et al., Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis, Atherosclerosis, 146, 257, 1999.
18. Lacy, F., O’Connor, D.T., and Schmid-Schonbein, G.W., Plasma hydrogen peroxide production in hypertensive and normotensive subjects at genetic risk of hypertension, J. Hypertens., 16, 291, 1998.
19. Swei, A. et al., Oxidative stress in the Dahl hypertensive rat, Hypertension, 30, 1628, 1997.
20. Keidar, S. et al., Angiotensin II stimulates macrophage-mediated oxidation of low density lipoprotein, Atherosclerosis, 115, 201, 1995.
21. Keidar, S., and Attias, J., Angiotensin II injection into mice increases the uptake of oxidized LDL by their macrophages via a proteoglycan-mediated pathway, Biochem. Biophys. Res. Commun., 239, 63, 1997.
22. Keidar, S. et al., The angiotensin II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E deficient mice, Biochem. Biophys. Res. Commun., 236, 622, 1997.
23. Hayek, T. et al., Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E deficient mice, J. Cardiovasc. Pharmacol., 31, 540, 1998.
24. Xiao, F., Puddefoot, J.R., and Vinson, G.P., Aldosterone mediates angiotensin II stimulated rat vascular smooth muscle cell proliferation, J. Endocrinol., 165, 533, 2000.
25. Ullian, M.E., Schelling, J.R., and Linas, S.L., Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses, Hypertension, 20, 67, 1992.
26. Dzau, V.J. et al., Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure, Circulation, 63, 645, 1981.
27. Bertrand, M.E., Provision of cardiovascular protection by ACE inhibitors: a review of recent trials, Curr. Med. Res. Opin., 20, 1559, 2004.
28. Pitt, B. et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N. Engl. J. Med., 341, 709, 1999.
29. Keidar, S. et al., Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensinconverting enzyme and the receptors for angiotensin II and aldosterone, Circulation, 109, 2213, 2004.
30. Hayek, T. et al., Omapatrilat decreased macrophage oxidative status and atherosclerosis progression in atherosclerotic apolipoprotein E-deficient mice, J. Cardiovasc. Pharmacol., 43, 140, 2004.
31. Hayek, T. et al., Tissue angiotensin-converting-enzyme (ACE) deficiency leads to a reduction in oxidative stress and in atherosclerosis: studies in ACE-knockout mice type 2, Arterioscler. Thromb. Vasc. Biol., 23, 2090, 2003.
32. Keidar, S. et al., Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice, J. Cardiovasc. Pharmacol., 41, 955, 2003.
33. Marutsuka, K. et al., Role of thrombogenic factors in the development of atherosclerosis, J. Atheroscler. Thromb., 12, 1, 2005.
34. Warkentin, T.E., Hemostasis and atherosclerosis, Can. J. Cardiol., 11, Suppl C, 29, 1995.
35. Fuster, V. et al., Atherosclerotic plaque rupture and thrombosis. Evolving concepts, Circulation, 82(3 Suppl), II47, 1990.
36. Huo, Y. and Ley, K.F., Role of platelets in the development of atherosclerosis, Trends Cardiovasc. Med., 14, 18, 2004.
37. Fuster, V., Mechanisms of arterial thrombosis: foundation for therapy, Am. Heart. J., 135, S361, 1998.
38. Aviram, M., Platelets and the arterial wall lesion, Curr. Opin. Lipidol., 3, 344, 1992.
39. Aviram, M., LDL-platelet interaction under oxidative stress induces macrophage foam cell formation, Thromb. Haemost., 74, 560, 1995.
40. Nityanand, S. et al., Platelets in essential hypertension, Thromb. Res., 72, 447, 1993.
41. Nowak, J. et al., Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes, Circulation, 76, 6, 1987.
42. Manduteanu, I. et al., Increased adhesion of human diabetic platelets to cultured valvular endothelial cells, J. Submicrosc. Cytol. Pathol., 24, 539, 1992.
43. Aviram, M. et al., Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy, J. Cardiovasc. Pharmacol., 31, 39, 1998.
44. Broijersen, A. et al., Platelet activity in vivo in hyperlipoproteinemia - importance of combined hyperlipidemia, Thromb. Haemost., 79, 268, 1998.
45. Cyrus, T. et al., Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice, Circulation, 106, 1282, 2002.
46. Pratico, D. et al., Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice, Proc. Natl. Acad. Sci., 98, 3358, 2000.
47. Cayatte, A.J. et al., The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 20, 1724, 2000.
48. Calzada, C., Bruckdorfer, K.R., and Rice-Evans, C.A., The influence of antioxidant nutrients on platelet function in healthy volunteers, Atherosclerosis, 128, 97, 1997.
49. Cordova, C. et al., Influence of ascorbic acid on platelet aggregation in vitro and in vivo, Atherosclerosis, 41, 15, 1982.
50. Bruckdorfer, K.R., Antioxidants, lipoprotein oxidation, and arterial function, Lipids, 31, S83, 1996.
51. de Lorgeril, M. et al., The beneficial effect of dietary antioxidant supplementation on platelet aggregation and cyclosporine treatment in heart transplant recipients, Transplantation, 58, 193, 1994.
52. Mabile, L., Bruckdorfer, K.R., and Rice-Evans, C., Moderate supplementation with natural alpha-tocopherol decreases platelet aggregation and low-density lipoprotein oxidation, Atherosclerosis, 147, 177, 1999.
53. Steiner, M., Influence of vitamin E on platelet function in humans, J. Am. Coll. Nutr., 10, 466, 1991.
54. Hubbard, G.P. et al., Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway, J. Thromb. Haemost., 1, 1079, 2003.
55. Stangl, V. et al., The flavonoid phloretin suppresses stimulated expression of endothelial adhesion molecules and reduces activation of human platelets, J. Nutr., 135, 172, 2005.
56. Deana, R. et al., Green tea epigallocatechin-3-gallate inhibits platelet signaling pathways triggered by both proteolytic and non-proteolytic agonists, Thromb. Haemost., 89, 866, 2003.
57. Freedman, J.E. et al., Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release, Circulation, 103, 2792, 2001.
58. Petroni, A. et al., Inhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil, Thromb., Res., 78, 151, 1995.
59. Pace-Asciak, C.R. et al., The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease, Clin. Chim. Acta, 235, 207, 1995.
60. Dommimiczak, M.H., Hyperlipidemia and cardiovascular disease, Curr. Opin. Lipidol., 9, 609, 1998.
61. Grundy, S.M. et al., Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, J. Am. Coll. Cardiol., 44, 720, 2004.
62. Grundy, S.M., Alternative approaches to cholesterol-lowering therapy, Am. J. Cardiol., 90, 1135, 2002.
63. Gotto, A.M., Jr., Management of dyslipidemia, Am. J. Med., 112, 8A, 2002.
64. Gotto, A.M., Jr. and Gundy, S.M., Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data issues from the interdisciplinary council on reducing the risk for coronary heart disease, ninth council meeting, Circulation, 9, E1, 1999.
65. Gotto, A.M., Jr. and Brinton, E.A., Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update, J. Am. Coll. Cardiol., 43, 717, 2004.
66. Gotto, A.M., Jr., Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report, Circulation, 103, 2213, 2001.
67. Castelli, W.P. et al., Lipids and risk of coronary heart disease: The Framingham Study, Ann. Epidemiol., 2, 23, 1992.
68. Gordon, D.H. and Rifkind, B.M., High-density lipoprotein: the clinical implications of recent studies, N. Engl. J. Med., 321, 1311, 1989.
69. Assmann, G. and Nofer, J.R., Atheroprotective effects of high-density lipoproteins, Annu. Rev. Med., 54, 321, 2003.
70. Nofer, J.R. et al., HDL and arteriosclerosis: beyond reverse cholesterol transport, Atherosclerosis, 161, 1, 2002.
71. Brewer, H.B. et al., Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease, Arterioscler. Thromb. Vasc. Biol., 24, 1755, 2004.
72. Assmann, G. and Gotto, A.M., Jr., HDL cholesterol and protective factors in atherosclerosis, Circulation, 109, III8, 2004.
73. Barter, P., CETP and atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 20, 2029, 2000.
74. Aviram, M. et al., Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R, Arterioscler. Thromb. Vasc. Biol., 18, 1617, 1998.
75. Mackness, M.I. et al., Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase, Atherosclerosis, 104, 129, 1993.
76. Mackness, M.I. and Durrington, P.N., HDL, its enzymes and its potential to influence lipid peroxidation, Atherosclerosis, 115, 243, 1995.
77. Pietinen, P. and Huttunen, J.K., Dietary determinants of plasma high-density lipoprotein cholesterol, Am. Heart. J., 113, 620, 1987.
78. Mursu, J. et al., Dark chocolate consumption increases HDL cholesterol concentration and chocolate fatty acids may inhibit lipid peroxidation in healthy humans, Free. Radic. Biol. Med., 37, 1351, 2004.
79. Nicolosi, R.J. et al., Dietary effects on cardiovascular disease risk factors: beyond saturated fatty acids and cholesterol, J. Am. Coll. Nutr., 20, 421S, 2001.
80. Hannuksela, M.L., Liisanantti, M.K., and Savolainen, M.J., Effect of alcohol on lipids and lipoproteins in relation to atherosclerosis, Crit. Rev. Clin. Lab. Sci., 39, 225, 2002.
81. Lavy, A. et al., Effect of dietary supplementation of red or white wine on human blood chemistry, hematology and coagulation: favorable effect of red wine on plasma high-density lipoprotein, Ann. Nutr. Metab., 38, 287, 1994.
82. Navab, M. et al., The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL, J. Lipid. Res., 45, 993, 2004.
83. Kaplan, M. and Aviram, M., Oxidized low density lipoprotein: Atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase, Clin. Chem. Lab. Med., 37, 777, 1999.
84. Aviram, M., Oxidative modification of low density lipoprotein and atherosclerosis, Isr. J. Med. Sci., 31, 241, 1995.
85. Aviram, M., Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis and the antiatherogenicity of antioxidants, Eur. J. Clin. Chem. Clin. Biochem., 34, 599, 1996.
86. Parthasarathy, S. and Rankin, S.M., The role of oxidized LDL in atherogenesis, Prog. Lipid. Res., 31, 127, 1992.
87. Jialal, I. and Devaraj, S., The role of oxidized low density lipoprotein in atherogenesis, J. Nutr., 126, 1053S, 1996.
88. Steinberg, D., Low density lipoprotein oxidation and its pathobiological significance, J. Biol. Chem., 272, 20963, 1997.
89. Berliner, J.A. and Heinecke, J.W., The role of oxidized lipoproteins in atherosclerosis, Free. Radic. Biol. Med., 20, 707, 1996.
90. Witztum, J.L. and Steinberg, D., Role of oxidized low density lipoprotein in atherogenesis, J. Clin. Invest., 88, 1785, 1991.
91. Parthasarathy, S., Santanam, N., and Auge, N., Oxidized low-density lipoprotein, a two-faced janus in coronary artery disease?, Biochem. Pharmacol., 56, 279, 1998.
92. Albertini, R., Moratti, R., and De Luca, G., Oxidation of low-density lipoprotein in atherosclerosis from basic biochemistry to clinical studies, Curr. Mol. Med., 6, 579, 2002.
93. Herttuala, S.Y., Is oxidized low density lipoprotein present in vivo? Curr. Opin. Lipidol., 9, 337, 1998.
94. Steinberg, D. et al., Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity, N. Engl. J. Med., 320, 915, 1989.
95. Aviram, M. and Rosenblat, M., Oxidative stress in cardiovascular diseases: role of oxidized lipoproteins in macrophage foam cell formation and atherosclerosis, in Redox Genome Interactions in Health and Disease, Fuchs J., Podda, M., and Packer, L., eds., Marcel Dekker, New York, 2004, 557.
96. Kim, J.A. et al., Partial characterization of leukocyte binding molecules on endothelial cells induced by minimally oxidized LDL, Arterioscler. Thromb., 14, 427, 1994.
97. Khan, N.B.V., Parthasarathy, S., and Alexander, R.W., Modified LDL and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells, J. Clin. Invest., 95, 1262, 1995.
98. Rangaswamy, S. et al., Exogenous oxidized low density lipoprotein injures and alters the barrier function of endothelium in rats in vivo, Circ. Res., 80, 37, 1997.
99. Penn, M.S. and Chisolm, G.M., Oxidized lipoproteins, altered cell function and atherosclerosis, Atherosclerosis, 108, S21, 1994.
100. Witztum, J.L. and Steinberg, D., Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids, Proc. Natl. Acad. Sci. USA, 81, 3993, 1984.
101. Parthasarathy, S. et al., Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor, Arteriosclerosis, 6, 505, 1986.
102. Kaplan, M. and Aviram, M., Macrophage-mediated oxidation of LDL and atherogenesis: protective role for paraoxonases, in Cellular Dysfunction in Atherosclerosis and Diabetes - Reports from Bench to Bedside, Simionesco, M., Sima, A., and Popov, D., eds., Romanian Academy Publishing, Romania, 2004, 336.
103. Aviram, M. and Rosenblat, M., Macrophage mediated oxidation of extracellular low density lipoprotein requires an initial binding of the lipoprotein to its receptor, J. Lipid. Res., 35, 385, 1994.
104. Aviram, M. et al., Activation of NADPH oxidase is required for macrophage-mediated oxidation of low density lipoprotein, Metabolism, 45, 1069, 1996.
105. Aviram, M. and Fuhrman, B., LDL oxidation by arterial wall macrophages depends on the antioxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants, Mol. Cell. Biochem., 188, 149, 1998.
106. Fuhrman, B., Oiknine, J., and Aviram, M., Iron induces lipid peroxidation in cultured macrophages, increases their ability to oxidatively modify LDL and affect their secretory properties, Atherosclerosis, 111, 65, 1994.
107. Fuhrman, B. et al., Increased uptake of low density lipoprotein (LDL) by oxidized macrophages is the result of enhanced LDL receptor activity and of progressive LDL oxidation, Free. Radic. Biol. Med., 23, 34, 1997.
108. Jacob, R.A., Evidence that diet modification reduces in vivo oxidant damage, Nutr. Rev., 57, 255, 1999.
109. Aviram, M., Macrophage foam cell formation during early atherogenesis is determined by the balance between pro-oxidants and anti-oxidants in arterial cells and blood lipoproteins, Antioxid. Redox. Signal., 1, 585, 1999.
110. Halliwell, B., Free radicals, antioxidants and human disease: Curiosity, cause, or consequence, Lancet, 344, 721, 1994.
111. Stocker, R., Dietary and pharmacological antioxidants in atherosclerosis, Curr. Opin. Lipidol., 10, 589, 1999.
112. Futterman, L.G. and Lemberg, L., The use of antioxidants in retarding atherosclerosis: fact or fiction? Am. J. Crit. Care., 8, 130, 1999.
113. Gaziano, J.M., Antioxidant vitamins and cardiovascular disease, Proc. Assoc. Am. Physicians., 111, 2, 1999.
114. Fuhrman, B. and Aviram, M., Antiatherogenicity of nutritional antioxidants, Idrugs, 4, 82, 2001.
115. Aviram, M. et al., Dietary antioxidants against LDL oxidation and atherosclerosis development: protective role for paraoxonase, in Handbook of Experimental Pharmacology (HEP): Arteriosclerosis; Influence of Diet and Drugs, von Eckardstein, A., ed., 2005, 259.
116. Maor, I. et al., Plasma LDL oxidation leads to its aggregation in the atherosclerotic apolipoprotein E-deficient mice, Arterioscler. Thromb. Vasc. Biol., 17, 2995, 1997.
117. Cyrus, T. et al., Vitamin E reduces progression of atherosclerosis in low-density lipoprotein receptor-deficient mice with established vascular lesions, Circulation, 107, 521, 2003.
118. Rice-Evans, C.A. et al., The relative antioxidant activities of plant-derived polyphenolic flavonoids, Free. Radic. Res., 22, 375, 1995.
119. Van Acker, S.A.B.E. et al., Structural aspects of antioxidants activity of flavonoids, Free Radic. Biol. Med., 20, 331, 1996.
120. Fuhrman, B. and Aviram, M., Flavonoids protect LDL from oxidation and attenuate atherosclerosis, Curr. Opin. Lipidol., 12, 41, 2001.
121. Fuhrman, B. and Aviram, M., Polyphenols and flavonoids protect LDL against atherogenic modifications, in Handbook of Antioxidants Biochemical, Nutritional and Clinical Aspects, 2nd Edition. Cadenas, E., and Packer, L., eds., Marcel Dekker, New York, 2001, 303.
122. Rosenblat, M. et al., Macrophage enrichment with the isoflavan glabridin inhibits NADPH oxidase-induced cell-mediated oxidation of low density lipoprotein: A possible role for protein kinase C, J. Biol. Chem., 274, 13790, 1999.
123. Hertog, M.G. et al., Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study, Arch. Intern. Med., 155, 381, 1995.
124. Knekt, P. et al., Flavonoid intake and risk of chronic diseases, Am. J. Clin. Nutr., 76, 560, 2002.
125. Knekt, P. et al., Flavonoid intake and coronary mortality in Finland: a cohort study, Brit. Med. J., 312, 478, 1996.
126. Renaud, S. and de Lorgeril, M., Wine alcohol, platelets and the French paradox for coronary heart disease, Lancet, 339, 1523, 1992.
127. Aviram, M., Antioxidants in restenosis and atherosclerosis, Curr. Interven. Cardiol. Rep., 1, 66, 1999.
128. Hayek, T. et al., Reduced progression of atherosclerosis in the apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin, or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation, Arterioscler. Thromb. Vasc. Biol., 17, 2744, 1997.
129. Aviram, M. and Fuhrman, B., Wine flavonoids, LDL cholesterol oxidation and atherosclerosis, in Wine: a scientific exploration, Sandler, M. and Pinder, R.M., eds., Taylor & Francis, London, 2003, 140.
130. Fuhrman, B. et al., Licorice extract and its major polyphenol glabridin protect low density lipoprotein against lipid peroxidation: in vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein E-deficient mice, Am. J. Clin. Nutr., 66, 267, 1997.
131. Aviram, M., Vaya, J., and Fuhrman, B., Licorice root flavonoid antioxidants reduce LDL oxidation and attenuate cardiovascular diseases, in Herbal Medicines: Molecular Basis of Biological Activity and Health, Packer, L., Halliwel, B., and Nam Ong C., eds., Marcel Dekker, New York, 2004, 595.
132. Fuhrman, B. et al., Grape powder polyphenols attenuate atherosclerosis development in apolipoprotein E deficient (E0) mice and reduce macrophage atherogenicity, J. Nutr., 135, 722, 2005.
133. Fuhrman, B. et al., Ginger extract consumption reduces plasma cholesterol levels, inhibits LDL oxidation and attenuates development of atherosclerosis in the atherosclerotic apolipoprotein E deficient mice, J. Nutr., 130, 1124, 2000.
134. Langley, P., Why a pomegranate? Brit. Med. J., 321, 1153, 2000.
135. Aviram, M., Polyphenols from pomegranate juice, red wine and licorice root protect against lipids peroxidation and attenuate cardiovascular diseases, in Polyphenols 2000. XXth International Conference on Polyphenols, Martens, S., Treutter, D. and Forkmann, G., eds., Freising-Weihenstephan, Germany, 2002, 158.
136. Gil, M.I. et al., Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing, J. Agric. Food Chem., 48, 4581, 2000.
137. Ben Nasr, C., Ayed, N., and Metche, M., Quantitative determination of the polyphenolic content of pomegranate peel, Z. Lebensm. Unters. Forsch., 203, 374, 1996.
138. Aviram, M., Pomegranate juice as a major source for polyphenolic flavonoids and it is most potent antioxidant against LDL oxidation and atherosclerosis, in Proceedings of the 11th Biennal Meeting of the Society for Free Radical Research International, Monduzzi, S.p.A., ed., MEDIMOND, Paris, 2002, 523.
139. Aviram, M. et al., Pomegranate juice polyphenols decreases oxidative stress, lowdensity lipoprotein atherogenic modifications and atherosclerosis, Free Radic. Res., 36, (Supplement 1), 72, 2002.
140. Aviram, M. et al., Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: studies in atherosclerotic mice and in humans, Drugs Ex. Clin. Res., 28, 49, 2002.
141. Cerda, B. et al., Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice, Eur. J. Nutr., 42, 18, 2003.
142. Cerda, B. et al., Repeated oral administration of high doses of the pomegranate ellagitannin punicalagin to rats for 37 days is not toxic, J. Agric. Food Chem., 51, 3493, 2003.
143. Seeram, N.P., Lee, R., and Heber, D., Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice, Clin. Chim. Acta, 348, 63, 2004.
144. Perez-Vicente, A., Gil-Izquierdo, A., and Garcia-Viguera, C., In vitro gastrointestinal digestion study of pomegranate juice phenolic compounds, anthocyanins, and vitamin C, J. Agric. Food Chem., 50, 2308, 2002.
145. Aviram, M. et al., Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in the atherosclerotic apolipoprotein E-deficient mice, Am. J. Clin. Nutr., 71, 1062, 2000.
146. Kaplan, M. et al., Pomegranate juice supplementation to atherosclerotic mice reduces macrophages lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis, J. Nutr., 131, 2082, 2001.
147. de Nigris, F. et al., Beneficial effects of pomegranate juice on oxidation-sensitive genes and endothelial nitric oxide synthase activity at sites of perturbed shear stress, Proc. Natl. Acad. Sci. U.S.A., 102, 4896, 2005.
148. Aviram, M. et al., Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation, Clin. Nutr., 23, 423, 2004.
149. Kitiyakara, C. and Wilcox, C.S., Antioxidants for hypertension, Curr. Opin. Nephrol. Hypertens., 7, 531, 1998.
150. Duffy, S.J. et al., Treatment of hypertension with ascorbic acid, Lancet, 354, 2048, 1999.
151. Galley, H.F., Thornton, J., Howdle, P.D., Walker, B.E., and Webster, N.R., Combination oral antioxidant supplementation reduces blood pressure, Clin. Sci., 92, 361, 1997.
152. Singh, R.B. et al., Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease, J. Hum. Hypertens., 13, 203, 1999.
153. Aviram, M. and Dornfeld, L., Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure, Atherosclerosis, 158, 195, 2001.
154. He, K. et al., Inactivation of cytochrome P-450 3A4 by bergamottin, a component of grapefruit juice, Chem. Res. Toxicol., 11, 252, 1998.
155. Aviram, M., Kent, U.M., and Hollenberg, P.F., Microsomal cytochromes P450 catalyze the oxidation of low density lipoprotein, Atherosclerosis, 143, 253, 1999.
156. Polagruto, J.A. et al., Effects of flavonoid-rich beverages on prostacyclin synthesis in humans and human aortic endothelial cells: association with ex vivo platelet function, J. Med. Food, 6, 301, 2003.
157. Esmaillzadeh, A. et al., Concentrated pomegranate juice improves lipid profiles in diabetic patients with hyperlipidemia, J. Med. Food, 7, 305, 2004.
158. Chidambara Murthy, K.N., Jayaprakasha, G.K., and Singh, R.P., Studies on antioxidant activity of pomegranate (Punica granatum) peel extract using in vivo models, J. Agric. Food Chem., 50, 4791, 2002.
159. Aviram, M. et al., Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants, Free Radic. Biol. Med., 26, 892, 1999.
160. Berliner, J.A. et al., Atherosclerosis: basic mechanisms: Oxidation, inflammation and genetics, Circulation, 9, 2488, 1995.
161. Fuhrman, B., Volkova, N., and Aviram, M., Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase, Atherosclerosis, 161, 307, 2002.
162. Aggarwal, B.B. and Shishodia, S., Suppression of the nuclear factor ΚB activation pathway by spice-derived phytochemicals: reasoning for seasoning, Ann. N.Y. Acad. Sci., 1030, 434, 2004.
163. Schubert, S.Y., Neeman, I., and Resnick, N., A novel mechanism for the inhibition of NF-ΚB activation in vascular endothelial cells by natural antioxidants, FASEB J., 16, 1931, 2002.
164. Schubert, S.Y., Lansky, E.P., and Neeman, I., Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids, J. Ethnopharmacol., 66, 11, 1999.
165. Goldstein, J.L. and Brown, M.S., Regulation of the mevalonate pathway, Nature, 343, 425, 1990.
166. Brown, M.S. and Goldstein, J.L., A receptor-mediated pathway for cholesterol homeostasis. Science, 232, 34, 1986.
167. Krieger, M., The best of cholesterols, the worst of cholesterols: a tale of two receptors, Proc. Natl. Acad. Sci. USA, 4, 4077, 1998.
168. Fuhrman, B., Volkova, N., and Aviram, M., Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages, J. Nutr. Biochem., 16, 570, 2005.
169. Rosenblat, M., Hayek, T., and Aviram, M. Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages. Atherosclerosis 2006 (in press).
170. Rosenblat, M., Volkova, N., Coleman, R., and Aviram, M. Pomegranate byproduct administration to apolipoprotein e-deficient mice attenuates atherosclerosis development as a result of decreased macrophage oxidative stress and reduced cellular uptake of oxidized low-density lipoprotein. J. Agric. Food Chem. 54, 1928-1935, 2006.